About Oncoceutics

Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The first lead compound to result from this program is ONC201, a small molecule drug with a unique mechanism of action that causes significant anti-tumor activity in a variety of types of human cancer. On February 28, 2014 the U.S. Food and Drug Administration accepted the Company‚Äôs Investigational New Drug (IND) application for ONC201.  Oncoceutics and collaborative groups have received $4.6 million in grants over the last two years from the National Institutes of Health, the Pennsylvania Department of Health, and The Musella Foundation, and the company has leveraged an additional $5 million in partnership funding from academic medical research partners.